Magnetic Fields / TGF-β1 Cancer Research Results

MF, Magnetic Fields: Click to Expand ⟱

Features: Therapy

Magnetic Fields can be Static, or pulsed. The most common therapy is a pulsed magnetic field in the uT or mT range.
The main pathways affected are:
Calcium Signaling: -influence the activity of voltage-gated calcium channels.
Oxidative Stress and Reactive Oxygen Species (ROS) Pathways
Heat Shock Proteins (HSPs) and Cellular Stress Responses
Cell Proliferation and Growth Signaling: MAPK/ERK pathway.
Gene Expression and Epigenetic Modifications: NF-κB
Angiogenesis Pathways: VEGF (improving VEGF for normal cells)
PEMF was found to have a 2-fold increase in drug uptake compared to traditional electrochemotherapy in rat melanoma models

Pathways:
- most reports have ROS production increasing in cancer cells , while decreasing in normal cells.
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx,
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, VEGF↓(mostly regulated up in normal cells),
- cause Cell cycle arrest : TumCCA↑,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, GLUT1↓, LDH↓, HK2↓, PFKs↓, PDKs↓, ECAR↓, OXPHOS↓, GRP78↑, Glucose↓, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, FGF↓, PDGF↓, EGFR↓, Integrins↓,
- Others: PI3K↓, AKT↓, STAT↓, Wnt↓, β-catenin↓, ERK↓, JNK, - SREBP (related to cholesterol).
- Synergies: chemo-sensitization, chemoProtective, cytoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Non-Static Magnetic Fields (AC / Pulsed / Oscillating MF)

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	Reactive oxygen species (ROS)	↑ ROS (P→R); often sustained (G)	↑ ROS (P); ↔/↓ net ROS (R→G)	P, R, G	Upstream redox perturbation	MF perturbs electron/radical dynamics: normal cells often adapt (ROS setpoint ↓), cancer cells less so
2	NRF2 antioxidant response	↔ / insufficient NRF2 induction (R→G)	↑ NRF2 activation (R→G)	R, G	Adaptive redox defense	Explains mixed ROS direction in normal cells (initial ↑ then adaptive ↓)
3	Glutathione (GSH) homeostasis	↓ GSH (R→G)	↔ or transient ↓ (R) with recovery (G)	R, G	Redox buffering capacity	GSH depletion reflects sustained oxidative load; recovery indicates successful adaptation
4	Superoxide dismutase (SOD) / antioxidant enzymes	↔ or inadequate enzyme upshift (G)	↑ SOD/GPx/CAT capacity (G)	G	Longer-term antioxidant remodeling	Often the “endpoint” readout that correlates with ROS-normalization in normal tissue
5	Mitochondrial ETC / respiration	↓ ETC efficiency; ↑ electron leak (P→R)	↔ mild, reversible ETC perturbation (P→R)	P, R	Bioenergetic destabilization	ETC perturbation is a mechanistic bridge between MF exposure and ROS/ΔΨm changes
6	Mitochondrial membrane potential (ΔΨm / MMP)	↓ ΔΨm (R); may progress (G)	↔ preserved or reversible dip (R)	R, G	Mitochondrial dysfunction thresholding	ΔΨm loss typically follows ROS/ETC disruption rather than preceding it
7	Ca²⁺ signaling (VGCC / ER–mitochondria Ca²⁺ flux)	↑ dysregulated Ca²⁺ influx/transfer (P→R); overload may persist (G)	↑ transient Ca²⁺ signaling (P); homeostasis restored (R→G)	P, R, G	Stress signal amplification	Ca²⁺ dysregulation links ROS/ETC perturbation to ER stress and mitochondrial dysfunction (amplifies ΔΨm loss and UPR commitment)
8	Mitochondrial permeability transition pore (MPTP)	↑ MPTP opening propensity (R); sustained opening possible (G)	↔ transient or closed (R→G)	P, R, G	Commitment point for mitochondrial failure	MPTP opening integrates ROS, Ca²⁺ overload, and ΔΨm loss; acts as a threshold event converting reversible stress into irreversible mitochondrial dysfunction
9	ER stress / UPR	↑ ER stress (R); CHOP-commitment possible (G)	↑ adaptive UPR (R); resolves (G)	R, G	Proteostasis stress	Often downstream of ROS + Ca²⁺ handling perturbations
10	DNA damage (oxidative)	↑ damage markers (R→G)	↔ or repaired (G)	R, G	Checkpoint pressure	Generally secondary to ROS; interpret as stress consequence not “direct genotoxicity”
11	LDH / glycolytic flux	↓ glycolytic performance (R→G)	↔ flexible substrate switching (R→G)	R, G	Metabolic vulnerability	Redox imbalance can destabilize high-rate glycolysis in cancer-biased contexts
12	Thioredoxin system (Trx / TrxR)	↓ functional reserve / overload (R→G)	↔ preserved capacity (G)	R, G	Parallel antioxidant system stress	Useful when GSH-only does not explain redox phenotype

Time-Scale Flag: TSF = P / R / G
  P: 0–30 min (physical / electron / radical effects)
  R: 30 min–3 hr (redox signaling & stress response)
  G: >3 hr (gene-regulatory adaptation)

MPTP: opening represents a mitochondrial commitment event integrating ROS and Ca²⁺ stress; sustained opening indicates irreversible bioenergetic failure.

TGF-β1, Transforming Growth Factor-Beta 1: Click to Expand ⟱

Source:

Type:

TGF-β1 is one of three TGF-β ligands (β1, β2, β3) that initiate the TGF-β signaling cascade.
In the context of cancer, TGF-β1 plays a dual role:
Tumor Suppressor in Early Stages: In normal and early-stage tumor cells, TGF-β1 typically inhibits cell proliferation, induces apoptosis, and maintains tissue homeostasis.
Tumor Promoter in Advanced Stages: As cancer progresses, TGF-β1 often promotes epithelial-to-mesenchymal transition (EMT), enhances invasiveness, contributes to immune evasion, and fosters a pro-metastatic microenvironment.

Role in Early Tumorigenesis: Acts as a tumor suppressor via growth arrest and apoptosis.
Role in Advanced Cancers: Promotes EMT, invasion, metastasis, and immune suppression.
Expression in Cancer Types: Increased in advanced/ aggressive tumors in many cancer types.
Prognostic Implications Elevated TGF-β1: associated with poor prognosis in several cancers due to its pro-tumorigenic functions.
Therapeutic Targeting Blocking TGF-β1 activity (via antibodies or ligand traps) to reduce its tumor-promoting actions.

Scientific Papers found: Click to Expand⟱

204-

MFrot,

MF,

Rotating magnetic field improved cognitive and memory impairments in a sporadic ad model of mice by regulating microglial polarization

in-vivo,

AD,

 0.2T, 4Hz

 reduced aluminum deposition in the brains of AD mice

*NF-kB↓, *MAPK↓, *TLR4↓, *memory↑, *cognitive↑, *TGF-β1↑, *ARG↑, *IL4↑, *IL10↑, *IL6↓, *IL1↓, *TNF-α↓, *iNOS↓, *ROS↓, *NO↓, *MyD88↓, *p‑IKKα↓, *p‑IκB↓, *p‑p65↓, *p‑JNK↓, *p‑p38↓, *ERK↓, *neuroP↑, *Aβ↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Total Targets: 0

Pathway results for Effect on Normal Cells:

Functional Outcomes ⓘ

cognitive↑, 1, memory↑, 1, neuroP↑, 1,
Total Targets: 25

Scientific Paper Hit Count for: TGF-β1, Transforming Growth Factor-Beta 1

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:172  Target#:1099  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

Magnetic Fields / TGF-β1 Cancer Research Results

Pathway results for Effect on Cancer / Diseased Cells:

Pathway results for Effect on Normal Cells:

Redox & Oxidative Stress ⓘ

Cell Death ⓘ

Proliferation, Differentiation & Cell State ⓘ

Migration ⓘ

Angiogenesis & Vasculature ⓘ

Immune & Inflammatory Signaling ⓘ

Protein Aggregation ⓘ

Clinical Biomarkers ⓘ

Functional Outcomes ⓘ

Home Page